Investigational drug · Phase 2
SYN321
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Osteoarthritis of Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "SYN321"
First trial start
2025
Aug 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYN321", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteoarthritis of Knee
Approved drugs for the same conditions: Osteoarthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "SYN321" as an intervention, largest first.
Synartro ABIndustry
NCT06989645 · 35 participants · Start Aug 19, 2025 · Primary completion Feb 2, 2026
Drug: SYN321; Placebo · For: Osteoarthritis of Knee
Sites: Uppsala, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- An Advanced Mechanically Active Osteoarthritis-on-Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study.
Palma C, Piazza S, Visone R, et al. · Adv Healthc Mater 2024
- In vivo joint synovial fluid disposition of a novel sustained-release formulation of diclofenac and hyaluronic acid in horses.
Rhodin M, Haubro Andersen P, Holm Forsström K, et al. · J Vet Pharmacol Ther 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.